Intuitive Surgical (NASDAQ:ISRG) Trading Up 1.4% – Still a Buy?

Intuitive Surgical, Inc. (NASDAQ:ISRG)’s stock price rose 1.4% during trading on Wednesday . The company traded as high as $592.54 and last traded at $587.96. Approximately 424,673 shares traded hands during mid-day trading, a decline of 78% from the average daily volume of 1,904,234 shares. The stock had previously closed at $579.65.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on ISRG shares. Stifel Nicolaus increased their price target on Intuitive Surgical from $525.00 to $610.00 and gave the stock a “buy” rating in a report on Thursday, December 5th. Leerink Partners raised their target price on Intuitive Surgical from $490.00 to $548.00 in a report on Monday, January 27th. Truist Financial upped their price objective on Intuitive Surgical from $640.00 to $666.00 and gave the stock a “buy” rating in a research report on Friday, January 24th. BTIG Research increased their price target on Intuitive Surgical from $535.00 to $561.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. Finally, Raymond James raised their target price on Intuitive Surgical from $560.00 to $688.00 and gave the stock an “outperform” rating in a research report on Friday, January 24th. One research analyst has rated the stock with a sell rating, five have given a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $613.10.

Intuitive Surgical Stock Down 0.9 %

The firm has a market capitalization of $207.65 billion, a PE ratio of 90.95, a P/E/G ratio of 5.51 and a beta of 1.39. The firm’s 50 day moving average price is $554.03 and its two-hundred day moving average price is $513.12.

Insider Activity

In other news, EVP Robert Desantis sold 376 shares of the company’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $539.00, for a total value of $202,664.00. Following the sale, the executive vice president now owns 5,506 shares in the company, valued at approximately $2,967,734. This represents a 6.39 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Jamie Samath sold 269 shares of the stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $539.89, for a total value of $145,230.41. Following the transaction, the insider now directly owns 8,757 shares in the company, valued at approximately $4,727,816.73. This represents a 2.98 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 5,940 shares of company stock worth $3,333,485 over the last ninety days. Corporate insiders own 0.80% of the company’s stock.

Institutional Investors Weigh In On Intuitive Surgical

Several institutional investors and hedge funds have recently made changes to their positions in ISRG. Berbice Capital Management LLC bought a new stake in shares of Intuitive Surgical during the 4th quarter valued at about $26,000. BankPlus Trust Department bought a new position in shares of Intuitive Surgical during the fourth quarter valued at approximately $28,000. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Intuitive Surgical during the 4th quarter worth approximately $31,000. Godsey & Gibb Inc. lifted its holdings in shares of Intuitive Surgical by 140.0% in the 3rd quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 35 shares during the last quarter. Finally, MidAtlantic Capital Management Inc. acquired a new position in Intuitive Surgical during the 3rd quarter valued at approximately $33,000. 83.64% of the stock is owned by institutional investors and hedge funds.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.